Can a radioactive antibody light up hidden cancers on PET scans?

NCT ID NCT07728942

Recruiting now Diagnosis Sponsor: Solve Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether a new imaging agent called SLR-108 can improve PET scans for people with metastatic solid tumors. SLR-108 is an antibody that carries a small amount of radioactivity and is designed to attach to tumor cells, making them more visible on a PET scan. The study aims to find the best dose and timing for clear images. About 70 adults with advanced solid tumors that have spread and are no longer responding to prior treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an antibody-radionuclide conjugate called SLR-108, used with a PET scanner to visualize tumors
What this could lead to: If successful, this imaging approach could help doctors see metastatic tumors more clearly, potentially guiding better treatment decisions.
What could go wrong: This is an early phase 1 trial, so the optimal dose and timing are still being worked out. The approach may not improve imaging enough to be useful, and there are unknown safety risks from the radioactive component.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMORS

Contacts and locations

Locations

Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.